Pharmacological agents are being developed to modulate phosphotyrosyl (pTyr)-dependent cell signalling. Emphasis is on inhibitors of pTyr- dependent binding interactions which are mediated by """"""""src homology 2"""""""" (SH2) domains and on protein-tyrosine phosphatase (PTP) inhibitors. Central to both of these efforts is the development of new pTyr mimetics which afford either increased stability toward enzymatic degradation by PTPs or increased affinity. In the SH2 domain area, development of cell- permeable Grb2 antagonists is being undertaken as potential new breast cancer therapeutics. For this work, peptidomimetics have been designed as conformationally constrained analogues of natural Grb2 SH2 domain- bound pTyr-containing peptides. In conjunction, a series of new pTyr- mimicking amino acid analogues have also been prepared to enhance cell permeability. In the phosphatase area, new PTP inhibitors have been designed and synthesized based on the X-ray structure of our lead small molecule inhibitor bound to the PTP1B enzyme. Some of these new inhibitors exhibit greater than 14-fold increased potency relative to the parent compound. X-ray structures of new inhibitors bound to the PTP1B enzyme have been obtained, allowing a precise determination of enzyme-inhibitor interactions. Utilizing this information along with computer-assisted molecular modelling, a further series of inhibitors is being developed. Emphasis is on deriving bioavailable agents which are selective for specific target PTPs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC006198-09
Application #
6100892
Study Section
Special Emphasis Panel (LMC)
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1998
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Liu, Fa; Park, Jung-Eun; Qian, Wen-Jian et al. (2011) Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. Nat Chem Biol 7:595-601
Liu, Fa; Park, Jung-Eun; Lee, Kyung S et al. (2009) Preparation of orthogonally protected (2S, 3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) as a phosphatase-stable phosphothreonine mimetic and its use in the synthesis of Polo-box domain-binding peptides. Tetrahedron 65:9673-9679
Jiang, Sheng; Liao, Chenzhong; Bindu, Lakshman et al. (2009) Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity. Bioorg Med Chem Lett 19:2693-8
Cao, Xuefei; Plasencia, Carmen; Kanzaki, Atsuko et al. (2009) Elucidation of the molecular mechanisms of a salicylhydrazide class of compounds by proteomic analysis. Curr Cancer Drug Targets 9:189-201
Liu, Fa; Worthy, Karen M; Bindu, Lakshman K et al. (2007) Structural examination of ring-closing metathesis-derived 15-member macrocycles as Grb2 SH2 domain-binding tetrapeptide mimetics. J Org Chem 72:9635-42
Giubellino, Alessio; Gao, Yang; Lee, Sunmin et al. (2007) Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. Cancer Res 67:6012-6
Kang, Sang-Uk; Choi, Won Jun; Oishi, Shinya et al. (2007) Examination of acylated 4-aminopiperidine-4-carboxylic acid residues in the phosphotyrosyl+1 position of Grb2 SH2 domain-binding tripeptides. J Med Chem 50:1978-82
Choi, Won Jun; Shi, Zhen-Dan; Worthy, Karen M et al. (2006) Application of azide-alkyne cycloaddition 'click chemistry' for the synthesis of Grb2 SH2 domain-binding macrocycles. Bioorg Med Chem Lett 16:5265-9
Dharmawardana, Pathirage G; Peruzzi, Benedetta; Giubellino, Alessio et al. (2006) Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy. Anticancer Drugs 17:13-20
Kang, Sang-Uk; Shi, Zhen-Dan; Worthy, Karen M et al. (2005) Examination of phosphoryl-mimicking functionalities within a macrocyclic Grb2 SH2 domain-binding platform. J Med Chem 48:3945-8

Showing the most recent 10 out of 37 publications